Month: September 2026

Five-Year Software Licensing and Support Renewal Expands Long-Standing Partnership

CALGARY, Alberta, Sept. 17, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG) today announced that it has entered into a five-year software licensing and software support agreement with Petroleo Brasileiro S.A. (“Petrobras”), Brazil’s largest oil and gas producer. The agreement renews and expands a prior agreement covering CMG’s reservoir and production simulation software.

Key Points:

• Five-year agreement. CMG and Petrobras have entered into a five-year agreement for reservoir and production simulation software licensing and support, renewing and expanding the companies’ previous agreement.
• A 40-year partnership. CMG and Petrobras have worked together since the 1980s and marked 40 years of partnership in 2026, making Petrobras one of CMG’s longest-standing customers.
• Coverage across a technically complex portfolio. Petrobras engineers use CMG software across ultra-deep offshore and pre-salt fields, reservoirs producing oil with high associated CO₂ content, and long-producing fields that require enhanced oil recovery methods.

“Forty years of working with the same partner has taught us a great deal,” said Pramod Jain, CEO of CMG. “Petrobras operates in some of the world’s most complex and technically demanding reservoirs and their engineers bring us problems that don’t have easy answers. Working through them together has moved our technology roadmap forward and built capability on both sides. This five-year agreement reflects our ongoing shared commitment to solving the challenges that come with developing assets like these.”

Under the renewed agreement, CMG’s simulation technology will continue to support Petrobras in evaluating recovery strategies and strengthening the subsurface analyses that inform long-term development and capital-allocation decisions.

“For decades, CMG has been an important technology partner supporting Petrobras in the evaluation and development of some of the world’s most complex reservoirs,” said Marcos Machado, Senior Technical Advisor at Petrobras. “This renewed agreement reflects our confidence in the value of advanced simulation technologies and strong technical collaboration to support sound subsurface decision-making across our portfolio.”

About CMG

CMG (TSX:CMG) is a global software and consulting company that combines science and technology with deep industry expertise to solve complex subsurface and surface challenges for the new energy industry around the world. CMG is headquartered in Calgary, AB, with offices in Houston, Oxford, Dubai, Bogota, Rio de Janeiro, Bengaluru, Kuala Lumpur, Oslo, Stavanger, and Kaiserslautern. For more information, please visit www.cmgl.ca.

Forward-Looking Statements

This press release contains “forward-looking statements”. Forward-looking statements can be identified by words such as: “aims”, “intend”, “can”, “goal”, “seek”, “believe”, “estimate”, “expect”, “strategy”, “future”, “likely”, “may”, “should”, “will”, and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. They are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements are detailed in the companies’ public filings.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable securities laws, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT: For investor inquiries, please contact:
Kim MacEachern
Director, Investor Relations
cmg-investors@cmgl.ca

For media inquiries, please contact:
marketing@cmgl.ca

Proposed listing aims to broaden investor access and expand future financing options

RENO, Nev., Sept. 17, 2026 (GLOBE NEWSWIRE) — Globaltech Corporation (OTCQB: GLTK) (“Globaltech” or the “Company”), a technology platform company building and commercializing AI, data and software solutions through its revenue-generating operating businesses, today provided an update on its planned Nasdaq Capital Market uplisting, including its listing application, completed reverse stock split and governance preparations.

Globaltech’s application to list its common stock on the Nasdaq Capital Market remains under review by Nasdaq. The Company has not received approval for the listing and does not currently meet Nasdaq’s uplisting requirements.

Management believes a Nasdaq listing could broaden Globaltech’s shareholder base, increase its visibility among institutional and retail investors, and improve trading liquidity over time. Access to a larger investor base could also expand future financing options to support commercialization of the Company’s AI, data and software platforms.

“We are pursuing a Nasdaq uplisting to attempt to expand the investor audience and financing opportunities available to Globaltech as we work to build and commercialize our technology platforms,” said Dan Green, Chief Executive Officer. “Our immediate focus is completing the listing preparations, meeting the uplisting requirements, and working through Nasdaq’s review, while strengthening the governance and reporting framework that we expect will support our next stage of development.”

Management continues to work through Nasdaq’s review and remains hopeful of completing the uplisting in the fourth quarter of 2026. Completion remains subject to Nasdaq approval, satisfaction of all applicable initial listing standards, market conditions, financing requirements and other customary conditions, however, there can be no assurance regarding the timing or completion of the uplisting.

As part of its preparations for the planned uplisting, the Company completed its previously announced 1-for-3 reverse stock split, effective August 27, 2026. The reverse split was intended to support the Company’s efforts to satisfy Nasdaq’s minimum share-price requirements; it does not by itself establish compliance with all listing standards.

The Company’s common stock continues to trade on the OTCQB Market while the Nasdaq application is under review. Following the reverse split, the stock is temporarily trading under the symbol “GLTKD” for 20 trading days through September 24, 2026, and is expected to revert to the symbol “GLTK” on September 25, 2026. The Company intends to retain “GLTK” upon a Nasdaq listing, subject to availability and applicable exchange requirements.

Globaltech is also strengthening its corporate governance, disclosure and internal controls in preparation for a potential Nasdaq listing. The Board has approved the formation of three committees: Audit, Compensation, and Nominating and Corporate Governance. Implementation is underway. These initiatives are intended to strengthen oversight, accountability and financial reporting as the Company prepares for the responsibilities of a Nasdaq-listed company.

If Nasdaq approves the application, the Company will announce the anticipated trading commencement date and related shareholder information in a Current Report on Form 8-K submitted to the U.S. Securities and Exchange Commission and an accompanying press release.

Shareholders and other interested investors can sign up to receive future press releases, including any Nasdaq listing announcement, by visiting www.globaltechcorporation.com/investor and selecting “Join Our Mailing List.”

About Globaltech Corporation

Globaltech Corporation (OTCQB: GLTKD; expected to revert to GLTK following the temporary post-reverse-split trading period) is a technology platform company building and commercializing AI, data and software solutions through its revenue-generating operating businesses. Its telecommunications and retail operations provide infrastructure, customer relationships and real-world environments to develop, test and scale technology platforms spanning financial technology, enterprise software, e-commerce and sports technology. Through its Center of Excellence, Globaltech evaluates, develops and commercializes technology opportunities across the platform. For more information, please visit www.globaltechcorporation.com.

Company Contact

Dan Green
Chief Executive Officer, Globaltech Corporation
investors@globaltechcorporation.com
Toll Free: (888) 760-7067
USA: (775) 624-4817

Forward-Looking Statements

Forward-looking statements in this release include the proposed Nasdaq listing, its timing and anticipated benefits, the expected trading symbol, governance preparations and future shareholder communications. These outcomes remain subject to uncertainty, including the Company’s ability to satisfy Nasdaq’s listing requirements and obtain approval.

Certain of the matters discussed in this communication which are not statements of historical fact constitute forward-looking statements that involve a number of risks and uncertainties. Words such as “strategy,” “expects,” “continues,” “plans,” “anticipates,” “believes,” “would,” “will,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify forward-looking statements but are not the exclusive means of identifying these statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Important factors that may cause actual results and outcomes to differ materially from those contained in such forward-looking statements include, without limitation: (a) our ability to uplist our common stock to Nasdaq, including the fact that we do not currently meet Nasdaq’s initial listing requirements, may not meet such requirements in the future, may not obtain approval of our application to list our common stock on Nasdaq on a timely basis, if at all, even if we meet all of the required quantitative listing requirements; (b) our strategic plans and treasury management initiatives; (c) risks relating to previously disclosed debt defaults and our ability to extend or refinance such debt, our need for additional capital, the terms of such capital and the potential dilution to stockholders caused thereby, including through the issuance of additional shares of common stock or upon conversion of outstanding convertible notes; (d) changes in consumer preferences, purchasing behavior, competitive conditions, and industry trends; (e) macroeconomic, geopolitical, and financial market conditions, including inflation, interest rates, tariffs, and consumer spending levels; (f) disruptions to sourcing, manufacturing, supply chain, logistics, labor availability, and the cost or availability of raw materials and finished goods; (g) the Company’s ability to successfully manage inventory, respond to changing fashion trends, maintain the strength of its brands, and execute its retail and growth strategies; (h) foreign currency exchange losses, fluctuations and translation risks related to our business in Pakistan and the United Kingdom; (i) the international economic environment, geopolitical developments and unexpected global events, including economic downturns in Pakistan, the United Kingdom and globally, changes in inflation and interest rates, tariffs, increased borrowing costs and potential declines in the availability of funding; (j) the greater political, legal and economic risks associated with operating in emerging markets as compared to more developed markets; (k) the unpredictability of our revenue performance, including because a significant majority of our customers have not entered into long-term fixed contracts with us; (l) our ability to compete in highly competitive markets, which we expect to become increasingly competitive, and our ability to expand our customer base and retain existing customers; (m) our ability to keep pace with technological changes and evolving industry standards; (n) cyber-attacks and other cybersecurity threats that may lead to compromised or inaccessible telecommunications, digital and financial services, leaks or unauthorized processing of confidential information, and the potential loss of customer confidence resulting therefrom; (o) the highly capital-intensive nature of the telecommunications industry and the substantial and ongoing capital expenditures required to operate and grow our business; (p) the terms of our interconnect agreements and our access to third-party-owned infrastructure and networks over which we have no direct control; (q) increases in license fees and our ability to obtain, maintain, renew or replace licenses, which may be suspended or revoked; (r) risks related to our ability to continue conducting our activities in a manner that does not cause us to be deemed an investment company under the Investment Company Act of 1940, as amended; (s) the loss of important intellectual property rights or third-party claims alleging infringement of intellectual property rights; (t) our substantial indebtedness and debt service obligations, which could materially decrease cash flow and adversely affect our business and financial condition; (u) our ability to maintain ownership and control of Worldcall Telecom Limited and 123 Investments Limited, as well as our status as a controlled company; (v) conflicts of interest; (w) our ability to comply with the extensive variety of laws and regulations applicable to our business and the uncertain judicial and regulatory environments in which we operate; (x) the fact that our operating subsidiaries, assets and certain of our officers and directors are located in Pakistan and the United Kingdom, which may affect shareholder rights, including the ability to enforce civil liabilities under U.S. securities laws; (y) the outcome of legal disputes, claims, investigations and litigation involving regulators, competitors and third parties; (z) risks relating to future divestitures, asset sales, joint ventures and acquisitions; (aa) the absence of an active trading market for our common stock and the risk that such a market may not develop or be sustained; (bb) future operating results; and (cc) other plans, objectives, expectations and intentions contained in this release that are not historical facts.

Other important factors that may cause actual results and outcomes to differ materially from those contained in the forward-looking statements included in this communication are described in Globaltech’s publicly filed reports, including, but not limited to, Globaltech’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, future Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. These reports are available at www.sec.gov. Globaltech cautions that the foregoing list of important factors is not complete. All subsequent written and oral forward-looking statements attributable to Globaltech or any person acting on behalf of Globaltech are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on Globaltech’s future results. The forward-looking statements included in this press release are made only as of the date hereof. Globaltech cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Globaltech undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by Globaltech. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

*3.38 G/T AUEQ (2.97 G/T AU, 1.80 G/T AG, 0.29 % CU) OVER 22 M, 0.95 G/T AUEQ (0.80 G/T AU, 1.11 G/T AG, 0.10 % CU) OVER 129.05 M

MONTREAL, Sept. 17, 2026 (GLOBE NEWSWIRE) — Troilus Mining Corp. (“Troilus” or the “Company”) (TSX: TLG; OTCQX: CHXMF; FSE: CM5), is pleased to announce the fourth batch of results from the Z87 optimization drill program at its Troilus Gold-Copper Project located in north-central Quebec, Canada. The results reported include nine drill holes totaling 4,728 metres, and form part of the 2026 exploration program outlined in the Company’s March 31, 2026 press release.

The ongoing Z87 optimization program is is targeting Inferred material and historically unsampled intervals within and around the current Z87 Reserve pit, with the objective of identifying opportunities to improve the mine plan presented in the Company’s Technical Report on September 9^th, 2026.

Importantly, the current Mineral Resource and Mineral Reserve estimates have an effective date of December 31, 2025, and therefore exclude all drilling completed in 2026. The results reported today continue to demonstrate mineralization in areas currently classified as Inferred or, in some cases, treated as waste in the existing block model, creating potential opportunities for resource conversion, pit and mining sequence optimization, strip ratio improvements and enhanced early-year mill feed.

Z87 Intercept Highlights:

• Hole 87-26-485 intersected 0.95 g/t gold equivalent (“AuEq”) (0.80 g/t Au, 1.11 g/t Ag, 0.10% Cu) over 129.05 m, including 3.38 g/t AuEq (2.97g/t Au, 1.80 g/t Ag, 0.29 % Cu) over 22 m starting at 398 m downhole from an area of inferred material within the Z87 reserve pit (see Figures 1 and 2).
• Hole 87-26-531 intersected 0.99 g/t gold equivalent (“AuEq”) (0.84 g/t Au, 1.20 g/t Ag, 0.10 % Cu) over 74.3 m, including 3.15 g/t AuEq (2.73 g/t Au, 1.88 g/t Ag, 0.30 % Cu) over 3.3m starting at 468 m downhole from an area of inferred material within the Z87 reserve pit (see Figures 1 and 2).
• Hole 87-26-529 intersected 1.15 g/t gold equivalent (“AuEq”) (1.00 g/t Au, 0.84 g/t Ag, 0.11 % Cu) over 45 m, including 5.42 g/t AuEq (4.73 g/t Au, 5.45 g/t Ag, 0.46 % Cu) over 2 m starting at 579 m from an area of inferred material 70 m below the Z87 reserve pit(see Figures 1 and 3).
• Hole 87-26-515 intersected several intervals of mineralization in the historically unsampled Z87 hangingwall where the current resource model does not contain mineralized blocks (see Figure 3 and Table 1).

Justin Reid, CEO of Troilus, commented, “None of our 2026 drilling is included in the latest Resource and Reserve estimates, and we continue to see impactful drill results from within and around the Z87 Reserve pit. We are targeting Inferred material and historically unsampled intervals, and the drilling is showing more extensive mineralization than is currently represented in the resource model. The results indicate mineralization in an area that is currently modeled as waste. Subject to further drilling, geological modelling, engineering evaluation and incorporation into future mine-plan updates, the mineralization may have the potential to reduce waste movement and improve strip ratios in this portion of the deposit.”.”

Z87 Optimization Program

Z87 was one of two zones previously mined by open pit during the former Troilus operation. Many of the historical drill holes used to define the former mine reserve were not continuously sampled, leaving intervals of core – in some cases extending for several hundred metres – without assay data.

For the purposes of resource estimation, these unsampled intervals are assigned values equal to one-half of the laboratory detection limit, resulting in significant gaps within the current block model. The 2026 optimization program is systematically testing these areas to determine whether mineralization extends through historically unsampled intervals that are presently modelled as waste.

The program is also targeting Inferred material within and around the current Z87 Reserve pit, with the objective of collecting data to support potential conversion to the Indicated category and consideration for possible incorporation into future Mineral Reserve and mine-plan updates.

The results announced today build on earlier 2026 drilling at Z87 that has demonstrated mineralization beyond and within the current Reserve pit, including broad intervals encountered in historically unsampled areas of the hangingwall (see press releases dated August 20, 2026, July 7, 2026 and June 25, 2026.)

All grades are uncut, and true thicknesses are approximately 75% to 90% of drilled length.

*The NI 43-101 technical report associated with the mineral Resources and Reserves of the Troilus Project can be found on SEDAR+ at www.sedarplus.ca under the Company’s issuer profile or on the Company’s website at www.troilusmining.com

Figure 1. Plan map with the reported drill hole locations from Z87

Figure 2. Cross section showing results for drillhole 87-26-485 and 87-26-531.

Figure 3. Cross section showing results for drillhole 87-26-515 and 87-26-529.

Z87 Drilling

Dillholes 87-26-485 was drilled to target inferred material within the Z87 reserve pit (see Figures 1 and 2). The main zone returned 129.05 metres grading 0.95 g/t AuEq including 3.38 g/t AuEq over 22 metres, which includes 4.34 g/t AuEq over 12.47 metres. This area of the reserve pit contains inferred blocks that are not incorporated into the current mine plan. This drilling was planned with the goal of upgrading the resource to the Indicated category for consideration in future production schedules.

On the same section, 120 metres down dip, drillhole 87-26-531 returned 125.5 metres grading 0.74 g/t AuEq, including 74.3 metres grading 0.99 g/t AuEq from the main zone of Z87, where it was targeting Inferred material. The hangingwall returned 20 metres grading 0.31 g/t AuEq and 41.4 metres grading 0.28 g/t AuEq where the current block model does not contain mineralization, as this area is informed by historically unsampled drillholes.

On a section 50m south of 87-26-485 and 87-26 531 (Figure 1), drillhole 87-26-529 returned 1.15 g/t AuEq over 45 metres within a broader zone of 0.51 g/t AuEq over 154 metres from the main zone of Z87 approximately 70 metres below the reserve pit (see Figure 3). This hole also returned 73 metres grading 0.35 g/t AuEq including 0.72 g/t AuEq over 13 metres from the Z87 hangingwall and 0.53 g/t AuEq over 40 metres including 1.54 g/t AuEq over 8 metres from the footwall. These intercepts present significantly broader mineralization than is currently in the resource model.

87-26-515 was drilled to target an area of historically unsampled material approximately 50 metres up dip of hole 87-26-529. This hole returned several intervals of mineralization where the current resource is unmineralized due to the impacts of historically unsampled intervals being assigned half the lab analysis detection limit for the purpose of resource estimation. These intercepts include 0.80 g/t AuEq over 8 metres including 1.48 g/t AuEq over 3 metres, 0.61 g/t AuEq over 12 metres including 1.52 g/t AuEq over 3.5 metres, 1.15 g/t AuEq over 7 metres including 5.04 g/t AuEq over 1 metres and 93 metres grading 0.46 g/t AuEq, which including intercepts of 1.07 g/t AuEq over 10 metres and 1.06 g/t AuEq over 10 metres.

To date, Troilus has released 39 drillholes totaling 14,521 metres of the approximately 24,000 metres allocated to the Z87 pit optimization program, which includes the targeting of Inferred and unsampled material within and around the reserve pit shell.

Table 1. Z87 Drill Results

Hole	From (m)	To (m)	Interval (m)	Au Grade (g/t)	Cu Grade (%)	Ag Grade (g/t)	AuEq Grade (g/t)
87-26-485(-47° dip)
	63	81	18	0.40	0.01	0.70	0.42
incl	68	69.38	1.38	2.95	0.04	5.00	3.07
	173.5	175	1.5	0.75	0.01	0.50	0.77
	214	221	7	0.20	0.02	0.38	0.23
	233	237	4	0.39	0.03	0.31	0.44
	257.77	273	15.23	0.22	0.03	0.47	0.27
	348	390	42	0.31	0.02	0.32	0.33
	398	527.05	129.05	0.80	0.10	1.11	0.95
incl	449	471	22	2.97	0.29	1.80	3.38
incl	456.18	468.65	12.47	3.91	0.30	1.82	4.34
incl	500	501	1	2.70	0.37	4.40	3.26
	533	563	30	0.61	0.05	1.15	0.69
incl	540	545	5	1.48	0.13	4.08	1.72
incl	543	544	1	2.99	0.21	8.10	3.38
	569	598	29	0.21	0.03	0.53	0.25
87-26-511(-51° dip)
	24	26	2	0.69	0.01	0.25	0.71
	34	51	17	0.43	0.01	0.34	0.45
incl	46	47	1	2.02	0.00	0.25	2.03
	58	67	9	0.17	0.02	0.35	0.21
	80	94	14	0.22	0.00	0.25	0.22
	115.5	117.5	2	0.65	0.00	0.25	0.66
	180	188	8	0.34	0.03	0.47	0.39
	236	240	4	0.52	0.00	0.25	0.53
87-26-515(-62° dip)
	32	38	6	0.28	0.01	0.25	0.30
	50.45	56	5.55	0.80	0.03	1.38	0.86
incl	50.45	51.36	0.91	3.75	0.06	3.00	3.87
	67	73	6	0.24	0.01	0.25	0.25
	98	105	7	1.52	0.01	0.71	1.55
incl	104	105	1	9.57	0.08	3.50	9.73
	141	149	8	0.77	0.02	0.51	0.80
incl	143	146	3	1.48	0.05	0.95	1.55
	190	194	4	0.50	0.00	0.25	0.51
	285	292	7	0.29	0.00	0.25	0.30
	299	324	25	0.22	0.01	0.54	0.24
	350	362.5	12.5	0.45	0.03	1.11	0.50
incl	362	362.5	0.5	7.08	0.00	0.25	7.09
	371	383	12	0.58	0.02	0.60	0.61
incl	371	374.5	3.5	1.49	0.02	0.86	1.52
incl	371	372	1	3.94	0.01	0.25	3.96
	388.5	396	7.5	0.22	0.01	0.25	0.23
	405	412	7	1.11	0.03	0.35	1.15
incl	406	407	1	4.98	0.04	0.70	5.04
	423	516	93	0.42	0.02	0.33	0.46
incl	447	457	10	0.96	0.07	0.69	1.07
incl	447	448	1	5.19	0.07	0.70	5.30
incl	456	457	1	1.77	0.31	2.10	2.21
incl	489	499	10	1.01	0.03	0.38	1.06
incl	490	491	1	3.79	0.08	1.50	3.92
87-26-529(-60° dip)
	130	148.15	18.15	0.47	0.02	0.76	0.52
incl	146	147	1	2.94	0.16	5.40	3.23
	205	209	4	0.34	0.00	0.25	0.34
	219	236	17	0.41	0.01	0.25	0.43
	245	250	5	0.22	0.00	0.25	0.22
	322.4	323	0.6	2.20	0.02	4.30	2.29
	382	455	73	0.31	0.02	0.51	0.35
incl	387	388	1	3.47	0.30	9.60	3.99
incl	424	437	13	0.64	0.06	0.78	0.72
	462	472	10	0.37	0.01	0.25	0.38
	480	487	7	0.22	0.01	0.30	0.24
	513	667	154	0.43	0.05	0.56	0.51
incl	579	624	45	1.00	0.11	0.84	1.15
incl	598	611	13	1.68	0.16	1.38	1.92
incl	598	600	2	4.73	0.46	5.45	5.42
incl	599	600	1	7.34	0.44	7.40	8.02
incl	610	611	1	5.81	0.09	1.10	5.94
	674	714	40	0.45	0.05	1.36	0.53
incl	688	696	8	1.41	0.08	1.23	1.54
incl	691	692	1	6.75	0.19	3.30	7.05
87-26-531(-60° dip)
	15	24	9	0.52	0.01	1.96	0.56
incl	15	16	1	2.32	0.01	3.10	2.38
	47	51	4	0.27	0.00	0.25	0.28
	71	82	11	0.30	0.00	0.31	0.31
	108	116	8	0.21	0.01	0.52	0.22
	251	251.5	0.5	2.07	0.00	4.90	2.14
	272	292	20	0.29	0.01	0.27	0.31
	313	354.4	41.4	0.26	0.01	0.54	0.28
	404	415	11	0.20	0.01	0.30	0.22
	423	548.5	125.5	0.64	0.07	0.95	0.74
incl	440	446	6	0.92	0.07	0.65	1.02
incl	468	542.3	74.3	0.84	0.10	1.20	0.99
incl	491	499.3	8.3	1.83	0.17	1.96	2.09
incl	496	499.3	3.3	2.73	0.30	1.88	3.15
incl	516	517	1	3.69	0.00	0.25	3.70
	560	586.5	26.5	0.44	0.06	1.45	0.54
incl	570	572	2	2.20	0.35	5.30	2.74
87-26-532(-64° dip)
	43	65	22	1.44	0.01	0.55	1.47
incl	48	61	13	2.25	0.01	0.61	2.27
incl	48	51	3	5.35	0.00	0.25	5.36
	122	125	3	0.43	0.00	0.25	0.44
	141	142	1	1.38	0.06	0.50	1.47
	240	242	2	3.68	0.01	1.05	3.70
	281	289	8	0.49	0.00	0.25	0.49
	350	377	27	0.36	0.01	0.34	0.38
incl	350	353	3	1.04	0.05	0.68	1.12
	393	408	15	0.49	0.03	0.32	0.53
incl	393	394	1	2.87	0.01	0.25	2.89
	439	457	18	1.66	0.02	0.27	1.69
incl	442	443	1	26.50	0.02	0.60	26.53
	464	542	78	0.64	0.09	1.04	0.78
incl	465	473	8	2.03	0.32	3.17	2.50
incl	468	473	5	2.64	0.42	4.42	3.26
incl	493	506	13	0.92	0.09	0.73	1.05
	564	566	2	0.94	0.03	0.53	0.99
	576	600	24	0.42	0.02	0.88	0.47
incl	591	592	1	2.74	0.02	2.70	2.80
incl	599	600	1	2.76	0.01	0.70	2.79
87-26-534(-53° dip)
	105	113	8	0.18	0.01	0.25	0.20
	140	154	14	0.33	0.01	0.28	0.34
incl	147	148	1	1.74	0.04	0.70	1.80
	185	210.6	25.6	0.47	0.01	0.27	0.48
incl	192	197	5	1.28	0.02	0.25	1.31
incl	208	208.5	0.5	3.95	0.00	0.25	3.96
	218	225	7	0.65	0.04	0.46	0.72
incl	223	224	1	2.66	0.03	0.25	2.70
	240	250	10	2.92	0.07	0.69	3.02
incl	242	243	1	2.32	0.00	0.25	2.33
incl	249	250	1	24.30	0.21	1.20	24.59
	269	270	1	1.08	0.01	0.25	1.09
	305	310	5	0.21	0.01	0.25	0.22
	317	330	13	0.46	0.03	0.31	0.50
	336	359	23	0.99	0.05	0.70	1.07
incl	339	340	1	3.57	0.06	3.10	3.69
incl	347	349	2	2.06	0.14	1.15	2.26
incl	356	358	2	5.23	0.19	2.35	5.52
	365	400	35	0.65	0.04	0.41	0.71
incl	371	390.9	19.9	0.91	0.05	0.50	0.99
incl	371	381	10	1.62	0.05	0.58	1.69
incl	380	381	1	7.66	0.03	0.50	7.71
	406	434	28	0.16	0.06	0.61	0.25
	450	471	21	0.92	0.04	0.86	0.98
incl	450	451	1	10.05	0.16	3.50	10.31
incl	459	460	1	2.37	0.09	1.10	2.50
	484	497	13	0.17	0.03	0.41	0.22
87-26-544(-55° dip)
	144	157	13	0.17	0.02	0.28	0.20
	160	164.5	4.5	0.20	0.03	0.34	0.25
	187.2	194.5	7.3	0.35	0.06	0.63	0.44
	222	225	3	1.48	0.06	2.23	1.59
	248	275	27	0.21	0.01	0.40	0.23
	282	286	4	0.37	0.03	0.54	0.42
	292	302	10	0.23	0.03	0.53	0.27
	309	314	5	0.84	0.03	0.54	0.88
incl	313	314	1	2.16	0.03	1.10	2.21
	332	336	4	0.21	0.05	0.60	0.28
	345	366	21	0.20	0.05	1.19	0.28
87-26-545(-55° dip)
	120	124	4	0.67	0.01	0.25	0.69
incl	122	123	1	1.61	0.01	0.25	1.62
	155	161	6	0.64	0.08	3.24	0.79
incl	157	158	1	2.30	0.16	10.50	2.66
	180	185	5	0.20	0.01	0.49	0.23
	245	254	9	0.49	0.01	0.28	0.51
incl	253	254	1	3.30	0.01	0.50	3.33
	286	299	13	0.22	0.05	0.42	0.30
	318	328	10	1.84	0.12	0.63	2.01
incl	318	322	4	4.21	0.22	1.01	4.51
incl	321	322	1	12.05	0.07	0.50	12.15
	334	348	14	0.30	0.09	0.72	0.44
	354	361	7	0.48	0.05	0.49	0.56
	367	396	29	0.46	0.02	0.69	0.50
incl	376	380	4	1.33	0.01	0.25	1.36
incl	376	377	1	3.19	0.01	0.25	3.20
	419	425	6	0.33	0.07	1.36	0.44
	435	436	1	3.22	0.00	0.50	3.23
incl	419	420	1	1.26	0.22	4.30	1.61

^{* AuEq = Au grade + 1.3365 * Cu grade + 0.0136 * Ag grade}

Quality Assurance and Control

During the drill program, one meter assay samples were taken from NQ core and sawed in half. One-half was sent for assaying at ALS Laboratory in Sudbury Ontario, a certified independent commercial laboratory, and the other half was retained for results, cross checks, and future reference. A strict QA/QC program was applied to all samples; which included insertion of one certified mineralized standard and one blank sample in each batch of 25 samples. Every sample was processed with standard crushing to 85% passing 75 microns on 500 g splits. Samples were assayed by one-AT (30 g) fire assay with an AA finish and if results were higher than 3.5 g/t Au, assays were redone with a gravimetric finish. For QA/QC samples, a 50 g fire assay was done. In addition to gold, ALS laboratory carried out multi-element analysis for ME-ICP61 analysis of 33 elements four acid ICP-AES.

Qualified Person

The technical and scientific information in this press release has been reviewed and approved by Nicolas Guest, P.Geo., Exploration Manager, who is a Qualified Person as defined by NI 43-101. Mr. Guest is an employee of Troilus and is not independent of the Company under NI 43-101.

AuEq Disclosure

The formulas used to calculate equivalent values for resources are as follows, for 87 Pit AuEq = Au + 1.3365*Cu +0.0136 Ag, for J Pit AuEq = Au + 1.3618Cu +0.0137 Ag, for SW Pit AuEq = Au + 1.3856Cu +0.01141 Ag, for X22 Pit AuEq = Au + 1.3168Cu +0.0136 *Ag. AuEq was calculated using metal prices of $2,415/oz Au; $4.60/lb Cu and $32.00/oz Ag and recoveries of 84.5% for Au, 86.9% for Ag and 88.1% for Cu in the J pit, 85.9% for Au, 87.6% for Ag and 87.9% for Cu in the 87 pit, 82.1% for Au, 87.1% for Ag and 87.1% for Cu in the SW pit and 85.6 % for Au, 87.0% for Ag and 86.3% for Cu in the X22 pit.

About Troilus Mining Corp.

Troilus Mining Corp. is a Canadian development-stage mining company focused on the systematic advancement of the former gold and copper Troilus Mine towards production. Troilus is located in the tier-one mining jurisdiction of Quebec, Canada, where it holds a large land position of 435 km² in the Frôtet-Evans Greenstone Belt. A technical report completed in September 2026 supports a large-scale 26-year, 50ktpd open-pit mining operation, positioning it as a cornerstone project in North America.

For more information:

Caroline Arsenault
VP Corporate Communications
+1 (647) 276-0050
info@troilusmining.com  

Cautionary Note Regarding Forward-Looking Statements and Information

This press release contains “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements regarding the impact of the drill results on the Company, the likelihood that the results will result in an improvement to the mine plan, the likelihood that mineralization in areas currently classified as Inferred will create potential opportunities for resource conversion, the results of the Technical Report, including, without limitation various project economics, financial and operational parameters such as the timing and amount of future production from the Project, expectations with respect to the IRR, NPV, payback and costs of the Project, anticipated mining and processing methods of the Project; proposed infrastructures, anticipated mine life of the Project, expected recoveries and grades, opportunity to expand the scale of the project, the project becoming a cornerstone mining project in Noth America; the development potential and timetable of the project; the estimation of mineral resources and reserves; realization of mineral resource and reserve estimates; the timing and amount of estimated future exploration; costs of future activities; capital and operating expenditures; success of exploration activities; the anticipated ability of investors to continue benefiting from the Company’s low discovery costs, technical expertise and support from local communities, the timing and amount of estimated future exploration; and the anticipated results of the Company’s 2026 drill program and their possible impact on the potential size of the mineral resource estimate. Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “continue”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved”. 

Forward-looking statements are made based upon certain assumptions and other important facts that, if untrue, could cause the actual results, performances or achievements of Troilus to be materially different from future results, performances or achievements expressed or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Troilus will operate in the future. Certain important factors that could cause actual results, performances or achievements to differ materially from those in the forward-looking statements include, amongst others, currency fluctuations, the global economic climate, dilution, share price volatility and competition. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of Troilus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: there being no assurance that the exploration program or programs of the Company will result in expanded mineral resources; risks and uncertainties inherent to mineral resource and reserve estimates; the high degree of uncertainties inherent to feasibility studies and other mining and economic studies which are based to a significant extent on various assumptions; variations in gold prices and other metals, exchange rate fluctuations; variations in cost of supplies and labour; receipt of necessary approvals; availability of financing for project development; uncertainties and risks with respect to developing mining projects; general business, economic, competitive, political and social uncertainties; future gold and other metal prices; accidents, labour disputes and shortages; environmental and other risks of the mining industry, including without limitation, risks and uncertainties discussed in the Company’s latest Annual Information Form, its technical reports and other continuous disclosure documents of the Company available under the Company’s profile at www.sedarplus.ca. Although Troilus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Troilus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/dee0a1c1-3e96-4fd7-bef4-396237e24508

https://www.globenewswire.com/NewsRoom/AttachmentNg/803a7ee1-e899-44f4-9cd8-8fac115290a9

https://www.globenewswire.com/NewsRoom/AttachmentNg/8d866bb1-4c22-4f4c-9625-c2d7dc7f4893

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce the successful closing of a non-brokered, strategic-level private placement (the “Offering”) of units of the Company (the “Units”). A total of 18,750,000 Units were sold under the Offering at a price of $0.40 per Unit (the “Issue Price”) for aggregate gross proceeds of $7,500,000.

Dr. Michael Gunning, Chief Executive Officer of the Company commented: “We are pleased to have successfully closed this financing and are appreciative of the continued support of our shareholders. We are excited to have this capital in order to immediately start the planning process for a drill program at our New Boston tungsten-moly-copper-silver polymetallic porphyry project in Nevada this fall, with a focus on following up on the recently announced intersection in drill hole NB26-003, and the goal of unlocking further value for shareholders in the near-term.”

Each Unit consists of one common share of the Company (each a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share (a “Warrant Share”) at a price of $0.65 (the “Exercise Price”) for a period of 24 months from the date of closing of the Offering (the “Closing Date”).

Proceeds of the Offering are intended to be used for follow-up exploration diamond drilling planned for this fall on its New Boston moly-copper-tungsten-silver porphyry project in Nevada, marketing, and general corporate and administrative expenses. In connection with the private placement and pursuant to the terms of an Agency Agreement dated April 24, 2026, the Company paid an aggregate cash fee of $506,000 to Centurion One Capital Corp. in connection which certain subscriptions.

The Common Shares and Warrants issued pursuant to the Offering and any Common Shares issued upon the exercise of Warrants are subject to a hold period of four months plus one day from the Closing Date.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ON BEHALF OF THE BOARD OF DIRECTORS

Dr. Michael H. Gunning
President & CEO

For general information please use the following:

Website www.vrr.ca
Email: info@vrr.ca
Phone: 778-731-9292

ABOUT VR RESOURCES LTD.

VR is an established junior exploration company based in Vancouver. VR evaluates, explores and advances opportunities in copper, gold and critical metals in Nevada, USA, and Ontario, Canada. VR applies modern exploration technologies, in-house experience, and expertise in greenfields exploration to large-footprint systems in underexplored areas/districts. The foundation of VR is the proven track record of its Board in early-stage exploration, discovery and M&A. VR owns its projects outright and evaluates new opportunities on an ongoing basis, whether by staking or acquisition.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

This news release contains statements that constitute “forward-looking statements”. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Forward-looking statements in this document include statements concerning the use of proceeds from the Offering, including statements regarding proposed drilling and other plans at the Company’s New Boston project, and all other statements that are not statements of historical fact.

Although the Company believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature, forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with: general economic conditions; adverse industry events; future legislative and regulatory developments in the mining sector; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; mining industry and markets in Canada; the ability of the Company to implement its business strategies; competition; and other assumptions, risks and uncertainties.

The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Trading in the securities of the Company should be considered highly speculative. All of the Company’s public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review them.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that it has commenced site preparation and early works construction activities at the Goldboro Gold Project (“Goldboro” or the “Project”) in Nova Scotia.

These activities are intended to de-risk the potential commencement of full-scale construction, which, if approved by the Company’s Board of Directors, is currently targeted to commence in Q1 2027. The Board’s final construction decision is currently anticipated to be considered during Q4 2026.

Site preparation and early works construction activities are primarily focused on establishing environmental controls and ensuring traditional community recreational access to areas during the planned period of construction following the final construction decision.

Activities include:

• Construction of elements of a public-access bypass road such as installation of culverts at water crossings;
• Installation of critical sediment and erosion control infrastructure;
• Tree clearing for the Employee Accommodations Facility pad, till and organics stockpiles, sedimentation ponds and the construction management facilities area; and
• Mobilization of site services contractors to support site construction activities.

NexGold has engaged the Mi’kma’ki-Municipal Limited Partnership in the execution of the site preparation and early works construction activities. The Mi’kma’ki-Municipal Limited Partnership is a majority Indigenous-owned partnership between Municipal Enterprises Limited (a subsidiary within the Municipal Group of Companies, and an affiliate of Dexter Construction Company Limited) and the 13 Mi’kmaw First Nations communities of Nova Scotia, represented by Wskijnu’k Mtmo’taqnuow Agency Limited.

Kevin Bullock, President, CEO & Director of NexGold, commented: “Commencing early works construction activities at Goldboro is a significant milestone for the Project and reflects the culmination of years of planning and development. We are also proud of our work with the Mi’kma’ki-Municipal Limited Partnership, which demonstrates our ongoing commitment to sustainable development, collaboration with the Mi’kmaq people of Nova Scotia, and investment in local communities.

“While key mine planning, engineering, procurement, community engagement, and recruitment activities remain ongoing, we are now prudently deploying capital toward activities designed to further de-risk Goldboro ahead of a potential construction decision.

“In parallel with these early works, we are finalizing the updated Feasibility Study to support a potential construction decision, both of which we are currently anticipating in the fourth quarter of 2026. We are also continuing to advance critical detailed engineering activities to support early construction contracts, procurement of long-lead equipment and various project execution planning initiatives.”

Construction and commissioning of Goldboro are expected to take approximately 26 months, leading to an operation with an 11-year open pit life of mine and average gold production of approximately 100,000 ounces per year. The Project is also expected to generate significant economic benefits for the region, including the creation of more than 300 on-site construction jobs, over 200 full-time on-site operational positions and more than 500 spin-off jobs annually during operations. The foregoing mine life, production and employment estimates are derived from the Company’s NI 43-101 Technical Report and Feasibility Study for the Project dated January 11, 2022 and are based on Mineral Reserves disclosed therein. Such estimates may be revised as a result of the updated Feasibility Study currently being finalized by the Company.

Qualified Persons

The scientific and technical information contained in this news release has been reviewed, verified and approved by Brian Jackson, P.Eng., Vice-President, Projects. Mr. Jackson is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About NexGold Mining Corp.

NexGold is a gold-focused company with assets in Canada and Alaska, including the Goldboro Gold Project in Nova Scotia, the Goliath Gold Complex (which includes the Goliath, Goldlund and Miller deposits) in Northwestern Ontario, and additional exploration projects across Canada. NexGold also holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project in southeast Alaska. NexGold is committed to ongoing, meaningful engagement with regional communities and Indigenous Nations to support sustainable development, safe operations, and shared economic and social benefits.

Further details about NexGold—including a Feasibility Study for the Goldboro Gold Project prepared by Nordmin Engineering Ltd., entitled “NI 43-101 Technical Report and Feasibility Study for the Goldboro Gold Project, Eastern Goldfields District, Nova Scotia” with an effective date of December 16, 2021 and a report date of January 11, 2022, and a Prefeasibility Study for the Goliath Gold Complex entitled “Goliath Gold Complex – NI 43–101 Technical Report and Prefeasibility Study” and dated March 27, 2023 with an effective date of February 22, 2023, led by independent consultants Ausenco Engineering Canada Inc.—are available under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on NexGold’s website at www.nexgold.com.

Contact:

Kevin Bullock President & CEO +1 (416) 214-4654 kbullock@nexgold.com

Greg DiTomaso Investor Relations +1 (647) 547-5357 gditomaso@nexgold.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of applicable U.S. securities laws (collectively, “forward-looking information”). Forward-looking information relates to future events or future performance and reflects management’s expectations or beliefs regarding future events and includes, but is not limited to, statements regarding: the timing, scope and completion of early works and site preparation activities at the Goldboro Gold Project (“Goldboro”); the expected benefits of such activities, including the de-risking of future construction activities; the timing and outcome of the Company’s updated feasibility study for Goldboro; the timing of a final construction decision by the Company’s Board of Directors; the anticipated commencement of full-scale construction activities; the advancement of detailed engineering, procurement activities and the acquisition of long-lead equipment; anticipated construction and commissioning schedules; projected mine life, gold production, employment and economic benefits associated with Goldboro; the Company’s development plans and objectives; and the Company’s objective of advancing Goldboro toward production.

Forward-looking information is often, but not always, identified by the use of words and phrases such as “anticipates”, “expects”, “plans”, “targets”, “budget”, “scheduled”, “estimates”, “intends”, “projects”, “believes”, “potential”, “future”, “opportunity”, “objective”, “on track”, “continue”, “may”, “will”, “would”, “could”, “should”, or similar expressions and includes statements that certain actions, events or results may, could, would, should or will occur or be achieved.

Forward-looking information is based on a number of assumptions, including, among other things: the timely completion of the updated feasibility study; the accuracy of current engineering, mine planning, cost and economic assumptions; the availability of financing on acceptable terms; the availability of labour, equipment and materials; the timely receipt of required regulatory approvals and permits; the ability to maintain positive relationships with Indigenous communities, local stakeholders, contractors and governmental authorities; the continued advancement of project development activities according to current expectations; and general business, economic and market conditions.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, without limitation: the risk that the Board of Directors does not approve a final construction decision; risks associated with the completion and results of the updated feasibility study; risks relating to project development and construction; cost overruns and schedule delays; risks relating to procurement and the availability of equipment, materials and contractors; the inability to secure financing on acceptable terms or at all; risks relating to permitting and regulatory approvals; risks relating to consultation and engagement with Indigenous communities and the timing or outcome of related agreements and approvals; labour shortages; inflationary pressures; health, safety and environmental risks; fluctuations in gold prices, commodity prices, currency exchange rates and capital markets; adverse economic conditions; and other risks disclosed in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca.

The early works activities described in this news release do not constitute a final construction decision with respect to Goldboro, and there can be no assurance that the Company’s Board of Directors will ultimately approve full-scale project construction.

In addition, references in this news release to anticipated mine life, gold production, construction schedule and economic benefits are based on the feasibility study entitled “NI 43-101 Technical Report and Feasibility Study for the Goldboro Gold Project, Eastern Goldfields District, Nova Scotia” with an effective date of December 16, 2021 and a report date of January 11, 2022. Such estimates may change as a result of the updated feasibility study currently being completed by the Company.

Although the Company believes that the assumptions and expectations reflected in the forward-looking information are reasonable, there can be no assurance that such information will prove to be accurate, and readers should not place undue reliance on forward-looking information. Actual results and future events may differ materially from those anticipated in such forward-looking information. Forward-looking information is made as of the date of this news release and, except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

• U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization
• KedRAB is One of Only Two FDA-Approved Anti-Rabies Immunoglobulin Products in the U.S. Market Estimated at $200 Million Annually
• Kamada’s Manufacturing Capacity and Supply Availability Positioned to Support Increased Demand

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (the “Company”), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today confirmed that it maintains sufficient KedRAB^® supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory published by the U.S. Centers for Disease Control and Prevention (CDC) on September 10, 2026, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis (PEP). The CDC Health Advisory is available at:
https://www.cdc.gov/han/php/notices/han00533.html.

In light of this increase in end-user utilization described in the CDC advisory, Kamada confirms it has the inventory and manufacturing capacity to support the continued supply of KedRAB, a human rabies immune globulin developed and manufactured by Kamada, which is one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. The product is supplied to the U.S. market via the Company’s U.S. commercialization partner, Kedrion Biopharma Inc.

“Kamada is a global leader in human rabies prevention using immunoglobulin and we remain committed to delivering reliable, uninterrupted supply of KedRAB to meet the needs of patients and clinicians across the United States,” said Amir London, Chief Executive Officer of Kamada. “Our long-standing successful partnership with Kedrion, together with our vertically integrated supply chain, and the recent FDA approval of our in-house rabies testing lab, position us to respond to this year-over-year increase in demand while maintaining the consistency and quality that this lifesaving therapeutic requires.”

Rabies is a deadly viral disease that attacks the brain and nervous system of mammals, including humans. The CDC estimates that approximately 1.4 million people in the United States seek medical care for a possible rabies exposure each year, of whom approximately 100,000 receive PEP treatment. Kamada estimates the total U.S. market for rabies immunoglobulin products at approximately $200 million annually.

INDICATION AND SELECTED IMPORTANT SAFETY INFORMATION
INDICATION: KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.

IMPORTANT SAFETY INFORMATION ABOUT KedRAB: Severe hypersensitivity reactions, including anaphylaxis, may occur with KedRAB. IgA deficient patients with antibodies against IgA are at greater risk. Have epinephrine available immediately to treat any acute severe hypersensitivity reactions. KedRAB administration may interfere with the development of an immune response to live attenuated virus vaccines. If feasible, delay immunization with the measles vaccine for 4 months, and other live attenuated virus vaccines for three months, after KedRAB administration. A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests after KedRAB administration. Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs’ test). KedRAB is made from human plasma donors and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-353-7466 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. I.D. Code: KAM.001-26

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third-parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: (1) the sufficiency of the Company’s KedRAB inventory and manufacturing capacity to meet current and future U.S. demand; and (2) expectations regarding continued or increased demand for KedRAB in the United States. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including, but not limited to: the unpredictable and seasonal nature of rabies exposure trends and the possibility that reported increases in demand do not continue or recur; Kamada’s reliance on Kedrion as its sole distributor of KedRAB in the United States and any change in that relationship; Kamada’s ability to manufacture sufficient quantities of KedRAB and to obtain adequate quantities of hyper-immune plasma and other raw materials on a timely basis; competition from other rabies immunoglobulin and rabies biologic products; the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world; the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally; the effect of tariffs on overall international trade and specifically on Kamada’s ability to maintain expected sales and profit levels in light of such tariffs; the effect on the establishment and timing of business initiatives; Kamada’s ability to leverage new business opportunities and integrate them with its existing product portfolio; unexpected results of clinical and development programs; regulatory delays; and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file with, or furnished to, the SEC and available on the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer’s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.

Details of the data presentations are as follows:

Alzheimer’s Disease Agitation:

• Title: Agitation in Alzheimer’s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-term Care
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Malcolm Fraser, MD, CMD, Medical Director, Red Rock Pharmacy, Salt Lake City, UT
  Poster Number: 139

• Title: Real-World Treatment Patterns and Clinical Management of Alzheimer’s Disease Agitation
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Amita Patel, MD, CMD, MHA, CPE, private practice, Dayton OH
  Poster Number: 145

• Title: Results of a Survey of Care Partners of People Living with Alzheimer’s Disease Agitation
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Brent P. Forester, MD, MSc; Professor, Department of Psychiatry, Tufts University School of Medicine, MA
  Poster Number: 146

Major Depressive Disorder:

• Title: Anti-Anhedonic Effects of Dextromethorphan-Bupropion Mediate Improvements in Functioning and Quality of Life in Major Depressive Disorder
  Presentation Date and Time: Thursday, September 17, 9:00 – 10:00 a.m. at the “Latest Discoveries & Emerging Trends in MDD” session, and 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Andrew Cutler, MD, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University, NY
  Poster Number: 75

• Title: Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg/105 mg)
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Joel L. Young, MD, Medical Director of the Rochester Center for Behavioral Medicine, MI
  Poster Number: 129

• Title: Anxiolytic Effects of Dextromethorphan-Bupropion (45mg/105mg): Post Hoc Analyses Across Trials in Major Depressive Disorder
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
  Poster Number: 101

• Title: Effects of Dextromethorphan-Bupropion (45mg/105mg) in Participants with Major Depressive Disorder and Anxious Distress
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
  Poster Number: 102

Excessive Daytime Sleepiness in Narcolepsy and OSA:

• Title: Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Wermter, Ellen E., FNP-BC, DBSM, FAASM, Restorative Sleep Medicine, Charlottesville, VA
  Poster Number: 156

Narcolepsy:

• Title: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Bruce Corser MD, FAASM, Medical Director of Intrepid Research, Cincinnati, OH
  Poster Number: 154

• Title: Symptom Burden and Quality of Life in Patients with Narcolepsy Who Continue to Experience Cataplexy: Subgroup Analysis from the CRESCENDO Survey
  Presentation Date and Time: Thursday, September 17, 12:00 – 3:30 p.m., and Friday, September 18, 12:00 – 3:30 p.m. Central Time
  Lead Author: Michael J. Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY
  Poster Number: 155

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI^®, AUVELITY^®, and SYMBRAVO^® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com

Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com

Latest publication adds to growing body of clinical evidence supporting hybrid IVUS-OCT imaging in complex coronary procedures

Chief Technology Officer Amandeep Thind to lead continued innovation

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced the publication of a peer-reviewed case report highlighting the clinical utility of hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging in guiding treatment decisions following stent placement. The case report, titled “Detection of Post-Stent Medial Dissection and White Thrombus Using Hybrid IVUS OCT Imaging may Help Guide Management,” was published in Catheterization and Cardiovascular Interventions. The report was authored by Megha Prasad, M.D., M.S., of Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, together with Khady N. Fall, M.D., Jeffrey W. Moses, M.D., and Natali Sorajja, M.S.

“Hybrid IVUS-OCT imaging provided complementary information that was important in assessing the post-stent findings in this case,” said Dr. Jeffrey Moses, author and Chairman of Cardiology at Good Samaritan University Hospital. “The ostial location necessitated IVUS for initial imaging. OCT was then essential in evaluating the dissections after stent placement. The distal medial edge dissection was easily visualized on OCT but less easily discernable on IVUS. IVUS alone may have failed to demonstrate the dissection, which required timely management. Having both modalities available helped guide management and apply treatment guidelines, including the decision to place an additional distal stent while managing the proximal dissection medically.”

The report describes the treatment of a 66-year-old patient undergoing percutaneous coronary intervention (“PCI”) of the right coronary artery. Following stent placement, the clinical team used Conavi’s hybrid IVUS-OCT imaging to identify proximal and distal edge dissections, as well as white thrombus. IVUS was used for vessel sizing and plaque assessment, while OCT’s higher resolution helped characterize the extent and depth of the dissections. IVUS also helped confirm an irregular protrusion seen on OCT as white thrombus rather than a calcified nodule. The authors noted that without identification of the thrombus, in-stent thrombosis could have led to further vessel occlusion and a potentially catastrophic event. The authors noted that this combined evaluation may be important in helping prevent acute vessel closure, major adverse cardiovascular events and target revascularization.

The latest publication is available at:
https://onlinelibrary.wiley.com/doi/10.1002/ccd.70821

“This case provides a very clear example of why combining IVUS and OCT can matter clinically,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “The two modalities provided complementary information that helped physicians identify and assess post-stent complications and determine when an additional stent was warranted and when medical management was appropriate. Together with other recent case reports, this publication adds to the clinical evidence supporting the potential value of hybrid imaging in complex coronary procedures.”

The publication follows other previously published case reports highlighting the use of Conavi’s hybrid IVUS-OCT technology in complex coronary interventions. In July 2026, a Journal of the Society for Cardiovascular Angiography & Interventions (“JSCAI”) case report highlighted the use of hybrid imaging in the contrast-sparing management of eruptive calcified nodules in a patient with impaired renal function. In July 2025, another JSCAI case report highlighted the use of hybrid imaging to identify plaque rupture and guide ostial stent placement in a complex coronary procedure. Together, these publications add to a growing body of clinical evidence highlighting the potential utility of hybrid IVUS-OCT imaging across a range of complex coronary procedures.

Previously Announced Case Reports
July 8, 2026 JSCAI case report, “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules”:
https://www.jscai.org/article/S2772-9303(26)01244-5/fulltext

July 30, 2025 JSCAI case report, “The Role of Comprehensive Hybrid Imaging in Identification of Plaque Rupture and Ostial Stent Placement: Case Report”:
https://doi.org/10.1016/j.jscai.2025.103814

Innovation Leadership Update
Amandeep Thind, Chief Technology Officer and Co-Founder, will assume leadership of Conavi’s research and development efforts. A co-inventor of the Company’s hybrid IVUS-OCT technology, Mr. Thind brings deep technical expertise and continuity as Conavi advances commercialization following the system’s recent FDA clearance.

Sumeet Dham, Vice President of Research and Development, will be departing the Company. Conavi thanks Mr. Dham for his years of leadership and valuable contributions to its technology and key development milestones, and wishes him continued success.

About Conavi Medical 
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/.

Notice on forward-looking statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

CONTACT:
Chief Financial Officer: Mark Quick, 416-483-0100
Investors: Christina Cameron, 416-483-0100 ext. 121, IR@conavi.com

New global research finds infrastructure constraints have surged more than fourfold since 2024 as enterprises race to operationalize AI

AUSTIN, Texas, Sept. 17, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today released findings from its 2026 Global Data Insights Survey (GDIS), which indicate that enterprises are increasingly facing infrastructure and governance challenges as they accelerate AI investment and deployment.

The research, based on responses from 2,131 IT decision-makers across 19 countries, found that 40% of IT decision-makers now identify lack of specialized infrastructure as the primary constraint on AI initiatives, a more than fourfold increase from just 9% in 2024. The figures underscore how rapidly enterprise priorities have shifted from AI strategy to AI execution. At the same time, enterprises are accelerating investment in AI and increasingly focusing on how to operationalize it at scale while balancing performance, governance, data sovereignty and cost control.

Respondents expect AI spending to increase by 32% over the next year and 79% expect to deploy AI initiatives in 2026. This comes as 3% of respondents report seeing no measurable return on investment (ROI) on investment from their AI initiatives and nearly two thirds (63%) expect to see returns within the next six months to two years.

98% percent of respondents expect to be running real-time AI applications within the next 12 months, which is expected to increase demand for low-latency connectivity and resilient infrastructure. As organizations move data and compute closer to business operations, 88% have adopted a distributed data strategy and 92% now tie data location decisions directly to AI plans, up from 73% in 2024. This reflects growing recognition that AI performance, governance and cost efficiency may depend increasingly on where data and infrastructure reside.

The survey also shows that concerns around data control and compliance are reshaping AI strategies globally. The majority (86%) of respondents say their organizations are pursuing sovereign AI initiatives, reflecting growing demand for greater control over where data and AI workloads reside. At the same time, more than 50% of respondents say their organizations now host AI workloads in private cloud environments, highlighting the growing importance of private AI architectures designed to support stronger governance, security and operational control.

“As organizations move decisively from strategy to execution, one factor emerges above all others as the determinant of success: infrastructure. Legacy data centers, built for a different era, cannot on their own meet emerging requirements for performance, compliance, scale, and security. The infrastructure beneath AI is now the gatekeeper between promise and payoff, and organizations that recognize this will be the ones who lead,” said Colin McLean, Chief Revenue Officer at Digital Realty.

The full report is available at Global Data Insights Survey | Digital Realty.

Methodology
The 2026 Global Data Insights Survey surveyed 2,131 IT decision-makers across 19 countries and eleven industries, including financial services, manufacturing, wholesale and retail trade, healthcare and pharmaceuticals, travel, transportation and logistics, business and professional services, energy and utilities, and media and entertainment. Respondents represented organizations with between 500 and more than 10,000 employees.

About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation, and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx®) solution methodology for powering innovation, from cloud and digital transformation to emerging technologies like artificial intelligence (AI), and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 55+ metros across 30+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

For Additional Information

Media Contacts
Helen Bleasdale
Digital Realty
+1 (737) 267-6822
hcbleasdale@digitalrealty.com

Investor Relations
Jordan Sadler / Jim Huseby
Digital Realty
+1 (737) 281-0101
InvestorRelations@digitalrealty.com

Safe Harbor Statement
This press release contains forward-looking statements which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially, including statements related to AI adoption, AI infrastructure demand, customer demand, expected customer benefits, PlatformDIGITAL®, data location strategies, Digital Realty’s strategy and the expected results or impact of the Global Data Insights Survey. For a list and description of risks and uncertainties, please see the company’s reports and other filings with the U.S. Securities and Exchange Commission. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

PARIS and NEW YORK and WHEAT RIDGE, Colo., Sept. 17, 2026 (GLOBE NEWSWIRE) — USA Rare Earth (Nasdaq: USAR), a rare earth, critical minerals and advanced materials company, Pasqal (Nasdaq: PSQL), a global leader in neutral-atom quantum computing and Riven Systems, a specialist in AI for industrial chemistry, today announced a strategic partnership to develop next-generation separation technology for the rare earth value chain. Using quantum machine learning, the project aims to identify new separation molecules that bind more effectively to rare earths than existing alternatives, enabling smaller, lower-cost, less energy-intensive processing facilities.

The collaboration brings together U.S. and French expertise in two strategically important sectors: critical minerals and quantum computing. Together, the companies aim to explore technologies that could help support a more secure, efficient and competitive Western rare earth supply chain.

The partnership brings together Riven’s self-driving minerals separation laboratory and Pasqal’s quantum computing power with USA Rare Earth’s rare earth processing expertise. Under the planned project, Riven would conduct thousands of automated experiments and generate the training data needed to build machine learning models of extractant selectivity for rare earth elements. Pasqal’s Neutral Atom QPU would then benchmark quantum machine learning models against classical computing-based models (each trained on data from the self-driving lab) to support USA Rare Earth in optimizing extractant selection.

“The key challenge the rare earth industry outside Asia faces is to separate the Mixed Rare Earth Carbonate (MREC) produced in upstream operations into individual, separated oxides. The Chinese dominate this capability, especially for vital heavy rare earths such as dysprosium, terbium and yttrium. Our goal is to accelerate the path to efficient, competitive and sustainable solutions by changing how the rare earth industry discovers the chemistry it runs on, replacing years of trial-and-error,” remarked Alex Moyes, Senior Vice President of Upstream (USA), USA Rare Earth. “This strategic partnership will institute an innovative discovery pipeline where new extractant molecules are identified and tested virtually, powered by a quantum machine learning model trained on real chemical data from an autonomous lab. Rapid discovery of an extractant built and optimized for USA Rare Earth’s flowsheets could improve our capital and operating efficiency by reducing stage count, equipment needs and raw material consumption, while lowering the carbon footprint and environmental impact of our facilities. Breakthroughs like these are what could help make a Western rare earth value chain possible and accelerate our journey to being competitive on the world stage.”

Pasqal and Riven will tailor their work to USA Rare Earth’s feedstocks, expected to include the Round Top mine in Sierra Blanca, Texas, as well as third-party mixed rare earth carbonates (MREC) and recycled cuttings (known as swarf) from the magnet manufacturing process. Targeting these key feedstocks means the experimental work can potentially impact all aspects of USA Rare Earth’s materials processing work.

“This partnership brings together three companies working at the forefront of technologies that are increasingly important to economic growth, industrial competitiveness and national resilience,” said Wasiq Bokhari, Chief Executive Officer of Pasqal. “Rare earth materials are essential and improving how they are processed has implications far beyond a single industry. By combining Pasqal’s quantum computing capabilities with USA Rare Earth’s materials expertise and Riven’s advanced automation platform, we have an opportunity to accelerate innovation while demonstrating how French and American companies can work together to strengthen critical supply chains.”

USA Rare Earth, Pasqal, and Riven believe this initial machine learning project could create opportunities for a deeper, extended collaboration. Over time, the companies envision a first-of-a-kind, end-to-end extractant discovery process: a quantum machine learning model identifies high-potential extractants, those extractants are tested in Riven’s self-driving lab, and top candidates are validated in USA Rare Earth’s R&D facility in Wheat Ridge, Colorado before being integrated in USA Rare Earth’s flowsheets.

“AI and autonomous labs are the next frontier in critical mineral processing,” said Dr. Orion Archer Cohen, CTO and co-founder of Riven Systems. “We applaud USA Rare Earth’s proactive adoption of these technologies, which forge a path to significant improvements over legacy chemistry. This is exactly how the West can leverage its lead in advanced compute technologies to reindustrialize faster.”

About USA Rare Earth, Inc.
USA Rare Earth, Inc. (Nasdaq: USAR) is building a fully integrated rare earth and permanent magnet value chain across the United States, Brazil and the United Kingdom. Through its ownership of Less Common Metals (LCM), one of the world’s leading producers of rare earth metals and alloys, its development of magnet manufacturing capacity in Stillwater, Oklahoma, the Pela Ema mine in Brazil and the Round Top deposit in Texas, USA Rare Earth operates across the entire value chain from mining to metal-making, alloy production and neodymium magnet manufacturing. USA Rare Earth is establishing a secure, Western-aligned supply of materials essential to the aerospace and defense, semiconductor, energy, data center, physical AI, mobility, healthcare and industrial sectors. For more information, visit www.usare.com.

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.
Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

About Riven Systems
Riven Systems builds chemical intelligence for industrial independence, with the immediate goal of leveraging AI and automation to bring critical minerals processing back to the West. The company is headquartered in New York City, NY. Learn more at rivensystems.ai.

Contacts
For USA Rare Earth:
Investor Relations Contact
J.B. Lowe, CFA
USA Rare Earth, Inc.
ir@usare.com

Media Relations Contact
Collected Strategies
Dan Moore / Scott Bisang
USAR-CS@collectedstrategies.com

For Riven:
Investors
contact@rivensystems.ai
Press
media@rivensystems.ai

For Pasqal:
Investors
investors@pasqal.com
Media
pr@pasqal.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those relating to the strategic partnership between USA Rare Earth, Pasqal and Riven as well as its mission, goals and planned methodology as well as the expected contribution of each party, the ability of quantum computing, AI and autonomous labs to be successfully applied to industrial applications, including to reduce the cost, energy use and complexity of rare earth processing; the anticipated implications, benefits and applications of any new separation molecules identified by the strategic partnership, the expected impact of any future extractant discovery process resulting from the strategic partnership on USA Rare Earth’s materials processing work and the rare earth value chain and other statements regarding USA Rare Earth’s and Pasqal’s expectations for future development, operations, strategies, transactions and financial performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “growth,” “intend,” “may,” “might,” “plan,” “potential,” “project,” “propose,” “should,” “target,” “vision,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to risks and uncertainties and potentially inaccurate assumptions that could cause actual results to differ materially from USA Rare Earth’s and Pasqal’s expectations, including without limitation: risks that the strategic partnership between USA Rare Earth, Pasqal and RIVEN may not yield viable molecule candidates on a timely basis or at all; risks that USA Rare Earth and Pasqal may not realize any of the anticipated benefits associated with the strategic partnership even if viable molecule candidates are identified; the risk that the application of quantum computing, AI and autonomous labs to industrial applications, such as advancing separation chemistry in rare earth processing, is novel and relatively untested; risks that USA Rare Earth may not realize the anticipated benefits of its combination with Serra Verde or its proposed and prior acquisitions, including expected synergies, financial performance, estimated earnings before interest, taxes, depreciation and amortization and, in the case of Serra Verde, integration of operations, on the anticipated timeline or at all; potential delays in the optimization and commissioning program and the Phase II expansion at the Pela Ema facility; political, economic, regulatory, tax, currency and other risks associated with Serra Verde’s operations in Brazil and Switzerland; physical climate risks related to the Pela Ema mine; the assumption of the Offtake Agreement and substantial indebtedness under Serra Verde’s Retained Finance Agreement, in each case which contains restrictive covenants and other requirements that could adversely affect the combined company’s financial flexibility and operations; risks that the Offtake Agreement is terminated or ceases to be in full force and effect or that the counterparty to the Offtake Agreement is insufficiently capitalized, including as a result of a failure to finalize definitive debt financing arrangements within the timeframes contemplated by the Offtake Agreement; risks that the proposed transaction with Carester SAS may not be consummated on its anticipated timeline or at all; the ability of USA Rare Earth’s Stillwater magnet manufacturing facility to generate revenue and the ability of USA Rare Earth’s planned Blacksburg facility to commence commercial operations on the timing and with the production capacity anticipated or at all; USA Rare Earth’s limited operating history; USA Rare Earth’s ability to commercially extract minerals from the Round Top deposit on its anticipated timeline or at all; differences between planned and actual recovery and yield rates; risks that USA Rare Earth may experience delays, unforeseen expenses, increased capital costs, and other complications while developing its projects; USA Rare Earth’s ability to raise necessary capital on acceptable terms or at all; potential dilution to existing stockholders and adverse effect on USA Rare Earth’s stock price if it issues additional common stock or equity-linked securities; the volatility of USA Rare Earth’s stock price; the availability of rare earth oxide, metal feedstock and other materials, utilities (including power and water) and equipment in quantities and prices that allow USA Rare Earth to develop and commercially operate its Stillwater facility and other facilities; USA Rare Earth’s ability to meet individual customer specifications and produce a consistently high quality product; potential supply chain, logistics or product delivery disruptions; any delays in obtaining or renewing permits and licenses; any changes in royalty rates or the imposition of new royalties; risks associated with community relations; fluctuations in demand for and prices of neo magnets, rare earth elements and USA Rare Earth’s other products, including without limitation as a result of dumping, predatory pricing and other tactics by USA Rare Earth’s competitors or state actors or the overall competitive environment; USA Rare Earth’s ability to achieve positive cash flow or profitability or the ability to access cash flow within its corporate structure due to restrictions contained in its financing agreements; USA Rare Earth’s ability to convert current commercial discussions and/or memorandums of understanding with customers for the sale of its neo magnets and other products into definitive orders; USA Rare Earth’s dependence, in part, on the growth of existing and emerging uses for neo magnets; the risk that additional manufacturing, refining and mining competitors could result in a reduction in revenue; geopolitical developments or disruptions, such as changes in the political environment, export/import or environmental policy of the People’s Republic of China, the United States or other countries in which USA Rare Earth operates or sells products or otherwise; USA Rare Earth’s designation on an export control list by China which has had and is expected to continue to have an adverse impact on its ability to source key raw materials and supplies from China; war, terrorism, natural disasters or public health emergencies; USA Rare Earth’s ability to retain or recruit key personnel; environmental, health and safety regulations; the receipt of funding from the U.S. Department of Commerce is subject to the achievement of milestones which may not be achieved on the expected timeline or at all; USA Rare Earth’s ability to comply with requirements for federal, state and local government incentives and financing; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; risks related to Pasqal’s indebtedness; and Pasqal’s ability to maintain, protect and defend its intellectual property rights

Additional risks and detailed information regarding factors that may cause actual results to differ materially has been and will be included in USA Rare Earth’s and Pasqal’s filings with the SEC, including USA Rare Earth’s most recently filed Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and subsequent filings, as well as Pasqal’s recently filed Registration Statement on Form F-1. Any forward-looking statements speak only as of the date of this press release (or such other date as is specified in such statements), and USA Rare Earth and Pasqal undertake no obligation to update any forward-looking statements as a result of new information or future events or developments.